Manufacturer of Rucaparib

Rucaparib was developed byClovis Oncology until it was sold to Pharmand GmbH (Pharma&) as part of the Clovis bankruptcy proceedings. In December 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the treatment of advanced ovarian cancer cases. It was approved for medical use in the European Union in May 2018 and was designated as an orphan drug, designed to treat recurrent or progressive ovarian cancer. Rucaparib is available by prescription only, and treatment should be initiated and supervised by a physician experienced in treating cancer. Rucaparib is available as a tablet and should be taken twice daily, and treatment should be continued until the cancer progresses or the patient experiences unacceptable side effects.